US Pharma MarketingWuXi Bio signs manufacturing deal with Viridian as Biosecure threat continues to erode
WuXi Biologics has secured a five-year contract with Viridian Therapeutics to manufacture and supply commercial batches of its monoclonal antibody veligrotug. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
WuXi Biologics has signed at least two new deals with notable US biotechs this year so far, signaling that the service provider is emerging from the shadow of the Biosecure Act.
The Chinese CDRMO has ...
Source: Endpoints News